Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
acute radiation syndrome treatment
market8 mentionslast seen Nov 2, 2026
Medical application domain for Entolimod development.
Relationships 2
Relationship
Entolimodapplies toacute radiation syndrome treatment
99% confidence8 supporting mentions
Either name opens that entity’s relationships.
Sources 8
- filingSEC EDGARNov 2, 2026Valion Bio, Inc. 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod is being developed as a potential medical countermeasure for both the hematopoietic (or bone marrow) and gastrointestinal ("GI") forms of acute radiation syndrome ("ARS")
- filingSEC EDGAROct 29, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod, which is designed to protect and mitigate both hematopoietic (bone marrow) and gastrointestinal ("GI") forms of acute radiation syndrome ("ARS")
- filingSEC EDGAROct 26, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome ("ARS")
- filingSEC EDGAROct 22, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod, Valion's lead biologic drug candidate for Acute Radiation Syndrome ("ARS")
- filingSEC EDGAROct 15, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome
- filingSEC EDGAROct 14, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
which is being developed as a potential medical countermeasure for Acute Radiation Syndrome
- filingSEC EDGAROct 6, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod is an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS)
- filingSEC EDGAROct 1, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion's investigational biologic aimed at protecting cells from severe damage or death from radiation exposure